Literature DB >> 17031644

Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins.

Attaphol Pawarode1, Suneet Shukla, Hans Minderman, Stacy M Fricke, Elaine M Pinder, Kieran L O'Loughlin, Suresh V Ambudkar, Maria R Baer.   

Abstract

PURPOSE: We sought to determine the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).
METHODS: Cellular content of mitoxantrone, a Pgp, MRP-1 and BCRP substrate, was measured by flow cytometry in cells overexpressing these proteins following incubation with and without CsA, tacrolimus or sirolimus. Interaction of BCRP with these compounds was studied by photolabeling and ATPase assays. Nuclear-cytoplasmic distribution of doxorubicin was studied by confocal microscopy in cells overexpressing LRP.
RESULTS: CsA increased cellular drug uptake in cells overexpressing Pgp, MRP-1 or BCRP and nuclear drug uptake in cells overexpressing LRP at the clinically achievable concentration of 2.5 microM. Tacrolimus enhanced cellular drug uptake at 1 microM, but not at 0.08 microM, its clinically achievable concentration, and did not enhance nuclear drug uptake. Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 microM, but was effective at its clinically achievable concentration of 0.25 microM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 microM. BCRP modulation by all three immunosuppressive agents was associated with competitive binding to the drug transport sites.
CONCLUSIONS: CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concentrations that differ from immunosuppressive concentrations and maximum tolerated concentrations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031644     DOI: 10.1007/s00280-006-0357-8

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

Review 1.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

Review 2.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

3.  Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.

Authors:  Tara C Gangadhar; Ezra E W Cohen; Kehua Wu; Linda Janisch; David Geary; Masha Kocherginsky; Larry K House; Jackie Ramirez; Samir D Undevia; Michael L Maitland; Gini F Fleming; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

Review 4.  The ABCG family of membrane-associated transporters: you don't have to be big to be mighty.

Authors:  Ian D Kerr; Ameena J Haider; Ingrid C Gelissen
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

5.  Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells.

Authors:  Ki-Hwan Eum; Michael Lee
Journal:  Mol Cells       Date:  2011-01-21       Impact factor: 5.034

6.  Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

Authors:  Petra Heffeter; Katharina Böck; Bihter Atil; Mir Ali Reza Hoda; Wilfried Körner; Caroline Bartel; Ute Jungwirth; Bernhard K Keppler; Michael Micksche; Walter Berger; Gunda Koellensperger
Journal:  J Biol Inorg Chem       Date:  2010-03-11       Impact factor: 3.358

7.  Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).

Authors:  Andaleeb Sajid; Natarajan Raju; Sabrina Lusvarghi; Shahrooz Vahedi; Rolf E Swenson; Suresh V Ambudkar
Journal:  Drug Metab Dispos       Date:  2019-08-01       Impact factor: 3.922

8.  Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting.

Authors:  O Moradi; I Karimzadeh; D Davani-Davari; M Shafiekhani; M M Sagheb; G A Raees-Jalali
Journal:  Int J Organ Transplant Med       Date:  2020

9.  Hypoxia as a target for drug combination therapy of liver cancer.

Authors:  Cressida Bowyer; Andrew L Lewis; Andrew W Lloyd; Gary J Phillips; Wendy M Macfarlane
Journal:  Anticancer Drugs       Date:  2017-08       Impact factor: 2.248

10.  Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA).

Authors:  Vigneshwaran Namasivayam; Katja Silbermann; Jens Pahnke; Michael Wiese; Sven Marcel Stefan
Journal:  Comput Struct Biotechnol J       Date:  2021-05-10       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.